Probal Banerjee | Biological Network | Best Researcher Award

Dr. Probal Banerjee | Biological Network | Best Researcher Award

The College of Staten Island (City University of New York) | United States

Dr. Probal Banerjee is a distinguished biochemist and neuroscientist whose academic and research career spans over four decades of excellence in bioorganic chemistry, molecular neuroscience, and cancer research. He earned his B.Sc. in Chemistry (Hons) and M.Sc. in Organic Chemistry from Jadavpur University, Calcutta, followed by a Ph.D. in Bioorganic Chemistry from the Indian Institute of Science, Bangalore in 1984. He completed postdoctoral research at the University of Notre Dame in Biochemistry and Enzymology and at the University of Chicago in Molecular Neuroscience. Currently a Professor of Chemistry and Coordinator at the Center for Developmental Neuroscience, College of Staten Island, CUNY, Dr. Banerjee has made pioneering contributions to understanding neurodevelopmental signaling and immune-modulating cancer therapies. His numerous honors include the Children’s Research Foundation Grant (1989), Brain Research Foundation Award, and two Dolphin Awards for Academic Excellence and Teaching. A sought-after speaker, he has delivered invited lectures at leading institutions worldwide on topics ranging from serotonin signaling in brain development to multi-target cancer therapeutics. Dr. Banerjee is also an inventor with several patents on curcumin-based anticancer agents and therapeutic approaches for Fragile X Syndrome. His expertise is widely recognized through his service on multiple NIH grant review committees, reflecting his enduring impact on neuroscience, pharmacology, and translational cancer research.

Profiles: Orcid 

Featured Publications

"Novel Taxol-Derivative, STO-1, Induces Selective Anti-Tumor Immunity and Sustained Remission of Glioblastoma Without Triggering Autoimmune Reactions", Shubhasmita Mohapatra; Adrian Guerrero; Neha Rahman; Khondoker Takia Zaman; Jing Wu; Callistus Onyeagba; Chanyue Hu; Matteo Pellegrini; Jayaram Vankudoth; Seiya Kitamura et al., Cells, 2025.

"One-Pot Synthesis of Phenylboronic Acid-Based Microgels for Tunable Gate of Glucose-Responsive Insulin Release at Physiological pH", Prashun G. Roy; Jiangtao Zhang; Koushik Bhattacharya; Probal Banerjee; Jing Shen; Shuiqin Zhou, Molecules, 2025.

"Biocompatible Anisole-Nonlinear PEG Core–Shell Nanogels for High Loading Capacity, Excellent Stability, and Controlled Release of Curcumin", Jing Shen; Jiangtao Zhang; Weitai Wu; Probal Banerjee; Shuiqin Zhou, Gels 2023.

"The G Protein-Coupled Serotonin 1A Receptor Augments Protein Kinase Cε-Mediated Neurogenesis in Neonatal Mouse Hippocampus-PKCε-Mediated Signaling in the Early Hippocampus", Sreyashi Samaddar; Sudarshana Purkayastha; Souleymane Diallo; Subramanyam J. Tantry; Ryan Schroder; Pranavan Chanthrakumar; Michael J. Flory; Probal Banerjee, International Journal of Molecular Sciences 2022.

"Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells", Sumit Mukherjee; Angela Fried; Rahman Hussaini; Richard White; Juliet Baidoo; Sri Yalamanchi; Probal Banerjee, Journal of Experimental & Clinical Cancer Research, 2018.

Nikhil Sudhir Sathe | Biological Networks | Best Researcher Award

Dr. Nikhil Sudhir Sathe | Biological Networks | Best Researcher Award

Reliance Life Sciences Pvt Ltd | India

Dr. Nikhil Sudhir Sathe (PhD), currently associated with Laboratory Animal Research Services (LARS), is a distinguished researcher with over 20 years of expertise in drug discovery and preclinical evaluation of new chemical entities. His extensive professional experience encompasses in vitro genotoxicology, cell and microbial culture (aerobic, anaerobic, and viral systems including rabies virus), and small laboratory animal studies. Throughout his career at Reliance Life Sciences, Vimta Labs, Dabur Research Centre, and Wockhardt Research Centre, Dr. Sathe has demonstrated exceptional proficiency in GLP-compliant laboratory practices, including bacterial reverse mutation, chromosomal aberration, micronucleus, ELISA, cytotoxicity, and microbial monitoring assays. His early research contributions involved innovative in vitro models for evaluating the efficacy of antimicrobial and cosmetic products. Academically, he holds a Master’s and Bachelor’s degree in Microbiology from Shivaji University, Kolhapur, both with distinction. Dr. Sathe has contributed significantly to scientific literature with publications in reputed journals such as Vaccine, Microbial Pathogenesis, Infectious Medicine, and BioMed, focusing on bacteriophage therapy and vaccine development against multidrug-resistant pathogens and SARS-CoV-2. His scholarly achievements are complemented by active participation in national conferences and workshops, reflecting his deep commitment to advancing microbiological and biomedical research.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

"Unveiling Lytic Bacteriophages as Promising Biotherapeutics for the Control of Multidrug-Resistant Pseudomonas aeruginosa", CS Nikhil Sathe, Eugene Athan, Arnab Kapat, BioMed, 2025.

"Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus", N Sathe, S Shaikh, M Bhavsar, L Parte, A Gadiparthi, S Kad, S Sensarma, Vaccine, 2024.

"Bacteriophage vB_kpnS-Kpn15: Unveiling its potential triumph against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae-Unraveling efficacy through innovative", N Sathe, C Suphioglu, E Athan, A Kapat, Microbial Pathogenesis, 2024.

"Pseudomonas aeruginosa: Infections and novel approaches to treatment “Knowing the enemy” the threat of Pseudomonas aeruginosa and exploring novel approaches to treatment", N Sathe, P Beech, L Croft, C Suphioglu, A Kapat, E Athan, Infectious medicine 2, 2023.

"Development of a novel therapy using bacteriophages: An alternative to antibiotics", NS Sathe, Deakin University, 2023.

Eman Kamal Ahmed Abdelall | Biological Network | Best Researcher Award

Dr. Eman Kamal Ahmed Abdelall | Biological Network | Best Researcher Award

Beni-Suef University | Egypt

Dr. Eman Kamal Ahmed Abdelall is a distinguished Professor of Pharmaceutical Organic Chemistry at Beni-Suef University, Egypt, with an outstanding academic and research career spanning over three decades. She earned her Ph.D. in Pharmaceutical Organic Chemistry from Cairo University in 2006 and has since advanced through academic ranks to become a full professor in 2018. Dr. Abdelall has held several key administrative positions, including Vice Dean of Student Affairs and Vice Dean for Environmental Affairs, and currently serves as the Head of the Department of Pharmaceutical Organic Chemistry. A prolific researcher, she has published over 53 peer-reviewed papers in leading journals indexed in Scopus and Google Scholar, with notable contributions to anti-inflammatory, anticancer, and antiviral drug design. Her excellence in scientific research has earned her numerous university honors, medals of excellence, and funded research awards. Dr. Abdelall is also an active reviewer for international journals, a member of higher education promotion committees, and a mentor who has supervised multiple Master’s and Doctoral theses, making her a leading figure in Egypt’s pharmaceutical research community.

Profiles: Scopus | Orcid | Google Scholar

Featured Publications

"Molecular docking, ADME study, Cardiovascular biomarkers and gastric safety of new pyrazoles as selective anti-inflammatory agents", EKA Abdelall, SS Zaghlool, JZF Saad, JN Philoppes, Journal of Molecular Structur, 2025.

"Synthesis of new selective agents with dual anti-inflammatory and SARS-CoV-2 Mpro inhibitory activity: Antipyrine-celecoxib hybrid analogues; COX-2, COVID-19 cytokine storm and replication inhibitory activities", EKA Abdelall, HAH Elshemy, MB Labib, JN Philoppes, FEM Ali, Bioorganic Chemistry, 2025.

"Synthesis and in silico studies of Novel thiophene–celecoxib hybrid with excellent cardiotoxicity and nephrotoxicity safety profiles", EKA Abdelall, PF Lamie, MB Labib, M El-Daly, A Mishrif, European Journal of Medicinal Chemistry, 2025.

"Novel quinoxaline derivatives as promising cytotoxic agents: structure-based design, in silico studies, VEGFR-2 inhibition, and PI3K/AKT/mTOR pathway modulation", EKA Abdelall, HAH Elshemy, H Abdelmegeed, N Ryad, AA Abdelaziz, Bioorganic Chemistr, 2025.

"The Role of Clinical Pharmacist in Monitoring Drug Therapy in the Cardiovascular and Coronary Care Units in Libya", ASH Alhomri, AA Battah, AA Elberry, EKA Abdelall, R Hussein", Pharmacy Practice, 2024.